Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series

Review Chemistry, Medicinal

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)

Uday Kiran Velagapudi et al.

Summary: The discovery of small molecules that inhibit PARP1 enzyme activity has led to the development of four marketed drugs for advanced-stage cancers. Exciting new findings in the field of PARP inhibitor discovery have emerged, aiming to reduce nonspecific interactions and potential toxicities. Recent progress in the development of PARP inhibitors, focusing on human cancers, is summarized and critically evaluated in this review, emphasizing on the evolution of conventional PARP inhibitor design towards potentially targeting multiple enzymes.

EXPERT OPINION ON THERAPEUTIC PATENTS (2021)

Add to Collection

Article Hematology

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

Pierre-Marie Morice et al.

Summary: The study found that PARP inhibitors increase the risk of myelodysplastic syndrome and acute myeloid leukaemia compared to placebo treatment. These delayed and often lethal adverse events should be further studied to improve clinical understanding, particularly in the front-line maintenance setting.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer

Deepak Singhal et al.

Summary: The study found that 13% of patients with hematological malignancies and other independent cancers had pathogenic germline variants (PGVs), with the most common being in CHEK2, BRCA1, DDX41, and TP53. Screening for PGVs can be triggered by a history of multiple cancers.

LEUKEMIA (2021)

Add to Collection

Letter Oncology